FocalTherics (NASDAQ:FOCL) Posts Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Posted by Stanley Muller on Aug 15th, 2026

FocalTherics (NASDAQ:FOCL – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19), FiscalAI reports. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The firm had revenue of $13.20 million for the quarter.

FocalTherics Stock Performance

Shares of FOCL traded up $0.13 during mid-day trading on Friday, reaching $4.76. 355,833 shares of the company were exchanged, compared to its average volume of 138,346. The stock has a 50 day simple moving average of $5.39. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The company has a market capitalization of $178.41 million, a PE ratio of -4.62 and a beta of -0.04. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40.

Institutional Trading of FocalTherics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Flax Pond Capital LLC acquired a new position in shares of FocalTherics in the 4th quarter worth approximately $2,623,000. Rock Springs Capital Management LP increased its position in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after buying an additional 91,500 shares during the period. Kovack Advisors Inc. bought a new position in FocalTherics during the fourth quarter worth $53,000. Lido Advisors LLC bought a new position in FocalTherics during the first quarter worth $40,000. Finally, SmartHarvest Portfolios LLC acquired a new position in FocalTherics in the first quarter valued at $38,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on FOCL. Piper Sandler reiterated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $7.75.

View Our Latest Report on FOCL

About FocalTherics

(Get Free Report)

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

Earnings History for FocalTherics (NASDAQ:FOCL)

Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.